Richard L Wasserman

Summary

Publications

  1. ncbi Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency
    Richard L Wasserman
    Pediatric Allergy Immunology Associates, Dallas, TX 75230, USA
    Eur J Pharm Sci 37:272-8. 2009
  2. ncbi Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease
    R L Wasserman
    DallasAllergyImmunology, Dallas, TX 75230, USA
    Clin Exp Immunol 161:518-26. 2010
  3. ncbi Diagnosis and treatment of primary immunodeficiency disease: the role of the otolaryngologist
    Richard L Wasserman
    Dallas Allergy Immunology, 7777 Forest Lane, Dallas, TX 75230, USA
    Am J Otolaryngol 32:329-37. 2011
  4. ncbi Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks
    Richard L Wasserman
    DallasAllergyImmunology, Dallas, Texas 75230, USA
    Ann Allergy Asthma Immunol 106:62-8. 2011
  5. ncbi Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency
    Richard L Wasserman
    Medical City Childrens Hospital, Dallas, Texas 75230, USA
    Clin Pharmacokinet 50:405-14. 2011
  6. ncbi Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease
    Richard L Wasserman
    Pediatrics Allergy Immunology Assoc, PA, Dallas, TX 75230, USA
    J Clin Immunol 31:323-31. 2011

Detail Information

Publications6

  1. ncbi Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency
    Richard L Wasserman
    Pediatric Allergy Immunology Associates, Dallas, TX 75230, USA
    Eur J Pharm Sci 37:272-8. 2009
    ..Administration of IgPro10 at 3- or 4-week intervals achieved sufficient plasma concentrations of total IgG, IgG subclasses and antibodies specific to important pathogens...
  2. ncbi Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease
    R L Wasserman
    DallasAllergyImmunology, Dallas, TX 75230, USA
    Clin Exp Immunol 161:518-26. 2010
    ....
  3. ncbi Diagnosis and treatment of primary immunodeficiency disease: the role of the otolaryngologist
    Richard L Wasserman
    Dallas Allergy Immunology, 7777 Forest Lane, Dallas, TX 75230, USA
    Am J Otolaryngol 32:329-37. 2011
    ..The objective of the study was to review the diagnosis and treatment of primary immunodeficiency disease (PID) and the role of otolaryngologists in the management of PID...
  4. ncbi Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks
    Richard L Wasserman
    DallasAllergyImmunology, Dallas, Texas 75230, USA
    Ann Allergy Asthma Immunol 106:62-8. 2011
    ..The symptoms of these painful attacks can be treated effectively with C1-INH concentrate...
  5. ncbi Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency
    Richard L Wasserman
    Medical City Childrens Hospital, Dallas, Texas 75230, USA
    Clin Pharmacokinet 50:405-14. 2011
    ..At the request of the US FDA, an algorithm for determining IgG trough level ratios (TLRs) was developed in order to provide physicians with a practical tool for monitoring doses during steady-state IgPro20 therapy...
  6. ncbi Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease
    Richard L Wasserman
    Pediatrics Allergy Immunology Assoc, PA, Dallas, TX 75230, USA
    J Clin Immunol 31:323-31. 2011
    ..Thus, subcutaneous replacement therapy with a 10% IgG preparation proved effective, safe and well-tolerated in our study population of subjects with primary immunodeficiency disease...